NASDAQ:IMNM Immunome (IMNM) Stock Price, News & Analysis $14.62 +1.08 (+7.98%) (As of 09/9/2024 ET) Add Compare Share Share Today's Range$13.63▼$14.7350-Day Range$11.70▼$16.5152-Week Range$6.65▼$30.96Volume518,122 shsAverage Volume778,024 shsMarket Capitalization$876.75 millionP/E RatioN/ADividend YieldN/APrice Target$29.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immunome alerts: Email Address Immunome MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside98.4% Upside$29.00 Price TargetShort InterestBearish25.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 2 Articles This WeekInsider TradingAcquiring Shares$97,580 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.92) to ($3.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.66 out of 5 starsMedical Sector614th out of 899 stocksPharmaceutical Preparations Industry283rd out of 420 stocks 3.5 Analyst's Opinion Consensus RatingImmunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunome has only been the subject of 2 research reports in the past 90 days.Read more about Immunome's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted25.61% of the float of Immunome has been sold short.Short Interest Ratio / Days to CoverImmunome has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Immunome has recently decreased by 8.93%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunome does not currently pay a dividend.Dividend GrowthImmunome does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMNM. Previous Next 1.8 News and Social Media Coverage News SentimentImmunome has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Immunome this week, compared to 3 articles on an average week.Search Interest2 people have searched for IMNM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunome insiders have bought 98.78% more of their company's stock than they have sold. Specifically, they have bought $97,580.00 in company stock and sold $49,089.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of Immunome is held by insiders.Percentage Held by Institutions44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunome's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunome are expected to decrease in the coming year, from ($1.92) to ($3.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunome is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunome is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunome has a P/B Ratio of 5.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunome's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Immunome Stock (NASDAQ:IMNM)Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Read More IMNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMNM Stock News HeadlinesAugust 20, 2024 | insidertrades.comImmunome, Inc. (NASDAQ:IMNM) Insider Jack Higgins Sells 3,524 SharesAugust 29, 2024 | finance.yahoo.comImmunome to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceSeptember 9, 2024 | Stansberry Research (Ad)How Boeing Disasters Could Impact NvidiaHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart midflight and catching fire. But, according to analyst Dan Ferris, there's something much darker going on here that could threaten Nvidia, the Magnificent 7, and the entire U.S. stock market.August 14, 2024 | finance.yahoo.comImmunome Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed on Immunome: Promising Clinical Trials and Strategic Growth ProspectsAugust 13, 2024 | finance.yahoo.comImmunome Reports Second Quarter 2024 Financial Results and Provides Business UpdateJuly 25, 2024 | finance.yahoo.comNectin Therapeutics Licenses Novel Antibodies to ImmunomeJuly 25, 2024 | finance.yahoo.comImmunome Provides Update on Recent Business Development Activity Expected to Expand ADC CapabilitiesSeptember 9, 2024 | Stansberry Research (Ad)How Boeing Disasters Could Impact NvidiaHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart midflight and catching fire. But, according to analyst Dan Ferris, there's something much darker going on here that could threaten Nvidia, the Magnificent 7, and the entire U.S. stock market.July 19, 2024 | finance.yahoo.comImmunome Insiders Added US$2.67m Of Stock To Their HoldingsJune 27, 2024 | seekingalpha.comImmunome: AL102 And Other Established Protein Targets Could Drive ValueJune 27, 2024 | seekingalpha.comImmunome: Enthusiasm For New Management Has FadedMay 24, 2024 | msn.comImmunome (NASDAQ:IMNM): An Opportunity for Investors with Strong StomachsMay 21, 2024 | finance.yahoo.comInsider Buying: Immunome Inc's CEO Acquires 100,000 SharesMay 20, 2024 | businesswire.comImmunome Announces Completion of Purchase of Assets from AtrecaMay 17, 2024 | msn.comImmunome appoints CFOMay 17, 2024 | businesswire.comImmunome Announces Promotion of Max Rosett to Chief Financial OfficerMay 16, 2024 | markets.businessinsider.comImmunome’s Promising Pipeline and Strategic Positioning Affirm Buy RatingSee More Headlines Receive IMNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/09/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMNM CUSIPN/A CIK1472012 Webimmunome.com Phone610-321-3700FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$29.00 High Stock Price Target$35.00 Low Stock Price Target$23.00 Potential Upside/Downside+99.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($7.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,810,000.00 Net Margins-2,435.02% Pretax Margin-2,435.02% Return on Equity-38.19% Return on Assets-29.63% Debt Debt-to-Equity RatioN/A Current Ratio7.12 Quick Ratio7.12 Sales & Book Value Annual Sales$14.02 million Price / Sales62.41 Cash FlowN/A Price / Cash FlowN/A Book Value$2.77 per share Price / Book5.26Miscellaneous Outstanding Shares60,050,000Free Float54,812,000Market Cap$874.93 million OptionableOptionable Beta1.77 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Clay B. Siegall Ph.D. (Age 63)President, CEO & Chairman Comp: $1.43MDr. Jack Higgins Ph.D. (Age 44)Chief Scientific Officer Comp: $956.34kDr. Robert J. Lechleider M.D. (Age 63)Chief Medical Officer Comp: $512.49kKey CompetitorsVir BiotechnologyNASDAQ:VIRIGM BiosciencesNASDAQ:IGMSEnlivex TherapeuticsNASDAQ:ENLVAimmune TherapeuticsNASDAQ:AIMTHUTCHMEDNASDAQ:HCMView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 1,256,833 shares on 8/19/2024Ownership: 0.642%Northeast Financial Consultants IncBought 72,953 shares on 8/16/2024Ownership: 0.122%Jean Jacques BienaimeBought 7,000 shares on 8/16/2024Total: $97,580.00 ($13.94/share)AXA S.A.Bought 179,688 shares on 8/15/2024Ownership: 0.300%The Manufacturers Life Insurance Company Bought 57,242 shares on 8/15/2024Ownership: 0.278%View All Insider TransactionsView All Institutional Transactions IMNM Stock Analysis - Frequently Asked Questions How have IMNM shares performed this year? Immunome's stock was trading at $10.70 at the beginning of 2024. Since then, IMNM shares have increased by 36.6% and is now trading at $14.62. View the best growth stocks for 2024 here. How were Immunome's earnings last quarter? Immunome, Inc. (NASDAQ:IMNM) posted its quarterly earnings data on Monday, August, 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.11. The business had revenue of $2.36 million for the quarter, compared to analyst estimates of $2.62 million. Immunome had a negative trailing twelve-month return on equity of 38.19% and a negative net margin of 2,435.02%. When did Immunome IPO? Immunome (IMNM) raised $30 million in an initial public offering on Friday, October 2nd 2020. The company issued 2,500,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Chardan acted as the underwriters for the IPO. Who are Immunome's major shareholders? Immunome's top institutional investors include Marshall Wace LLP (2.86%), Sofinnova Investments Inc. (1.09%), Victory Capital Management Inc. (0.82%) and Point72 Asset Management L.P. (0.64%). Insiders that own company stock include Michael Rapp, Bruce Turner and Jack Higgins. View institutional ownership trends. How do I buy shares of Immunome? Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMNM) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSell NVDA Now?Just weeks before last month’s selloff, Citadel – the most successful hedge fund in history – quietly sold 500...Chaikin Analytics | Sponsored‘Wheels Are Falling Off’ the U.S. Stock Market"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He ...Stansberry Research | SponsoredWall Street’s Best-Kept SecretWe're about to let you in on Wall Street's best-kept secret… For decades we've watched big institutions and...Unstoppable Prosperity | SponsoredCan Apple’s AI News Make You Rich?September 20th 2024: AI’s “iPhone Moment” Apple is making a major move on Friday, September 20th. And what ...Banyan Hill Publishing | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
